Direct Full-stage Implantation of Sacral Neuromodulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this investigator-initiated study is to investigate the efficacy and costs of direct full stage sacral neuromodulation in patients with overactive bladder. Patients with refractory OAB and urge urinary incontinence will undergo direct full stage implantation and be followed for a period of 6 months to monitor symptom improvement with voiding diaries and validated questionnaires preoperatively and postoperatively. Therapeutic and adverse outcomes will be evaluated. The use of medical resources and time off of work will be analyzed as well. This will be a descriptive study with no additional arms or randomization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless Neuromodulation

NCT02434874

Urinary Incontinence, Urge

WITHDRAWN NA

The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence

NCT02776475

Urinary Urge Incontinence

TERMINATED NA

Neuromodulation Implantation Settings Variation for Overactive Bladder

NCT02112786

Overactive Bladder

WITHDRAWN NA

Comparison of Motor and Sensory Response With Interstim Stimulation

NCT00943904

Overactive Bladder Urgency-Frequency

COMPLETED NA

Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System

NCT07247136

Urinary Urge Incontinence

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Bladder, Overactive Urge Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

overactive bladder patients

Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation

full stage implantation of sacral neuromodulation

Intervention Type DEVICE

full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

full stage implantation of sacral neuromodulation

full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \>18 years of age
* Female gender
* Refractory overactive bladder: wet failing treatment with two or more anticholinergic and/or beta-3 agonist agents
* Willing to stop treatment with anticholingeric and/or beta-3 agonist agents during the study period (2 week washout period preoperatively and 6 months postoperative)
* Willing and able to complete study questionnaires, use Medtronic device programmer, return for scheduled follow-up appointments
* Surgical candidate able to hold antiplatelet or anticoagulation prior to surgery
* Health insurance provider that will cover full-stage implantation

Exclusion Criteria

* Age \<18
* Pregnant or planning to become pregnant
* Male gender
* Unable or unwilling to stop anticholingeric and/or beta-3 agonist agents during the study period
* Treatment with botulinum toxin within last 6 months
* Recent surgery for stress urinary incontinence or pelvic organ prolapse within last 6 months
* Severe pelvic organ prolapse
* Post-void residual \>150 ml
* Symptomatic or recurrent urinary tract infection
* Neurologic disorders: cerebrovascular accident with neurologic deficits, Parkinson's, multiple sclerosis, spinal cord injury, significant peripheral neuropathy
* Cognitive disorders, e.g. dementia
* Interstitial cystitis or chronic pelvic pain syndrome
* Poorly controlled diabetes mellitus (HbA1c \>10%)
* History of bladder malignancy, pelvic radiation, urinary retention requiring catheterization
* Anticipated or known need for MRI at the trunk
* History of or anticipated surgery at the lower back
* Unable to hold antiplatelet or anticoagulation prior to surgery
* Life expectancy \<1 year

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No